Ideas

Natural product-therapy for Deafness: A therapeutic mix encompassing Xanthohumol, Cholecalciferol, Ajoene and DIM (XCAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via up regulation of its target genes, 4/January/2018, 7.27 am
Natural product-therapy for Deafness: A therapeutic mix encompassing Xanthohumol, Cholecalciferol, Ajoene and DIM (XCAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via up regulation of its target genes, 4/January/2018, 7.27 am 960 720 Dr Boomi's Genom-2-Discovery Center

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Natural product-therapy for Deafness: A therapeutic mix encompassing Xanthohumol, Cholecalciferol, Ajoene and DIM (XCAD)  increases the expression of ATG5 (Autophagy-related…

read more

Vitamin-based therapy for improving cardiac contractility and attenuating pathogenesis-associated with Myocardial infarction:   Phytonadione/Mephyton/VitaminK1  decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene, 4/January/2017, 6.17 am
Vitamin-based therapy for improving cardiac contractility and attenuating pathogenesis-associated with Myocardial infarction:   Phytonadione/Mephyton/VitaminK1  decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene, 4/January/2017, 6.17 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study, from Department of Medicine, Division of Cardiology, Dept of Cell Biology, and Department of Molecular Genetics, Duke University Medical Center, Durham, North Carolina,…

read more

Vitamin-based therapy for Inflammatory bowel disease(IBD): Vitamin A decreases the expression of oncostatin M, attenuates activation of oncostatin M- oncostatin M receptor pathway in inflamed colon tissues, inhibits inflammatory gene expression, attenuates colonic pathogenesis, and inhibits the progression of inflammatory bowel disease and colitis via down regulation of its target gene, 4/December/2017, 6.00 am
Vitamin-based therapy for Inflammatory bowel disease(IBD): Vitamin A decreases the expression of oncostatin M, attenuates activation of oncostatin M- oncostatin M receptor pathway in inflamed colon tissues, inhibits inflammatory gene expression, attenuates colonic pathogenesis, and inhibits the progression of inflammatory bowel disease and colitis via down regulation of its target gene, 4/December/2017, 6.00 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK shows that “Oncostatin…

read more

Molecular therapy for Cardiomyopathy: A pharmacological mixture encompassing VitaminK1 (Phytonadione/Mephyton) and Asprin (VKASP) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 4/January/2018,  5.48 am
Molecular therapy for Cardiomyopathy: A pharmacological mixture encompassing VitaminK1 (Phytonadione/Mephyton) and Asprin (VKASP) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 4/January/2018,  5.48 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say   A study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart function through microRNA-mediated Sox6 repression.” This…

read more

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  Astaxanthin, Epicatechin and Matrine (AEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 3/January/2018, 9.55 am
Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  Astaxanthin, Epicatechin and Matrine (AEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 3/January/2018, 9.55 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

read more

Vitamin-based therapy for Metabolic diseases: A pharmaceutical mixture [PMFA] encompassing Pyridoxamine(PM) and Folic acid (FA) increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, incrases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene., 3/January/2017, 9.43 am
Vitamin-based therapy for Metabolic diseases: A pharmaceutical mixture [PMFA] encompassing Pyridoxamine(PM) and Folic acid (FA) increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, incrases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene., 3/January/2017, 9.43 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.” This study was published, in the June 8, 2011 Nature [One of…

read more
Start Typing